Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Indivior Plc ADR (OP: INVVY )

N/A UNCHANGED
Last Price Updated: 10:23 AM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Indivior Plc ADR

Indivior Reaches $102.5M Settlement To Resolve Antitrust Litigation
Indivior PLC (OTCPK:INVVY) (OTCPK:IZQVF) (LSE: NDV), an addiction treatment company, announced that its subsidiary, Indivior Inc., has reached an agreement to resolve the claims brought by the... 
Via Benzinga
Activist Investor Recommends Yelp Explore Sale, Micron Projects China Ban To Curb Revenues, Spruce Point Capital Raises Concerns About Perion Network's Financial Practices: Today's Top News
Wall Street Journal 
Via Benzinga
Nasal-Spray Millionaire: Indivior's Opvee Nasal Spray Gets FDA Green Light for Opioid Overdose Treatment
The FDA has approved Indivior PLC's (OTC: INVVY) Opvee (nalmefene) nasal spray for the emergency treatment of opioid overdose in adults and pediatric patients aged 12 years and older. 
Via Benzinga
Indivior Acquires Opiant Pharmaceuticals Strengthening Its Addiction Treatment And Science Portfolio
Indivior PLC (OTCPK:INVVY) (LSE:INDV) has completed the acquisition of Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) The transaction strengthens Indivior's addiction treatment and science portfolio by... 
Via Benzinga
Indivior Targeting Listing On NASDAQ For The Spring Of 2023
Indivior PLC (OTCPK:INVVY) (LON:INDV) will hold a capital markets day on December 7th in New York City. The event will be hosted by Mark Crossley, CEO, along with members of the Indivior executive... 
Via Benzinga
Facebook Stalls Portal & Smartwatch Projects, Visa Breaks Debit Card Tie Up With FTX, $3B Bitcoin Withdrawn From Crypto Exchanges: Top Stories Monday, Nov. 14
Reuters 
Via Benzinga
Indivior To Pay Over 100% Premium To Buy Opioid Focused Player Opiant Pharmaceuticals
Via Benzinga
Hypocrisy All Around: Pfizer, NFL Are Hidden Sponsors Of Anti-Drug Group Fighting Against Cannabis Legalization
The Community Anti-Drug Coalitions of America (CADCA), which is fighting against federal cannabis legalization, recently removed a page on its website disclosing its partners. 
Via Benzinga
Indivior Positioned To Profit If Aelis Farma's Study Of Cannabis Use Disorder Succeeds
Indivior PLC (OTCPK:INVVY) (LON:INDV) announces the enrollment of the first patient in the Phase 2b study of AEF0117 for the treatment of cannabis use disorder (CUD). 
Via Benzinga
Indivior Study Shows Buprenorphine May Mitigate Fentanyl-Induced Respiratory Depression In Chronic Opioid Users
Indivior PLC  (OTCPK:INVVY) (LON:INDV) published modeling data examining the competitive interaction between buprenorphine, a treatment for opioid use disorder, and fentanyl, a potent synthetic opioid,... 
Via Benzinga
Cannabis Movers & Shakers: MedMen, IM Cannabis, Avicanna, Avant Brands
MedMen's CRO Tracy McCourt Named President Of Emerald Village West Hollywood Cannabis retailer MedMen Enterprises Inc. 
Via Benzinga
Using Opioid Addiction Drug Buprenorphine May Cause Dental Issues, FDA Flags
The FDA warned patients and prescribers about the risk of potential dental problems arising from the use of buprenorphine medicines to treat opioid addiction and pain.... 
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.